Share Price | Speciality Medicines Ltd Stock Analysis & Recommendation

Q: What does Speciality Medi. do?

Overview:Speciality Medicines Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.History:There are no details available regarding the incorporation year or any status changes. Additionally, no sales or profit data has been reported for the latest quarter.Financial Snapshot:Most recent Net Sales: N/AMost recent Net Profit: N/AMarket-cap value: INR 180 Cr (Micro Cap)Key Metrics:P/E: 14.00Industry P/E: 34Dividend Yield: 0.00%Debt-Equity: -0.25Return on Equity: 18.30%Price-to-Book: 2.65Contact Details:Registrar Address: Not available.

Q: How big is Speciality Medi.?

As of 10th June, Market Cap: Speciality Medicines Ltd has a market capitalization of 180.00 Cr, categorizing it as a Micro Cap company.Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 30.42 Cr and Total Assets valued at 39.98 Cr.

Q: Who are the peers of the Speciality Medi.?

Peers: The peers of Speciality Medi. are Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., Syschem (India), Brooks Lab., Oxygenta Pharma, Coral Labs., Sanjiv.Parant.Quality Snapshot: Below Average management risk is observed at Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., Syschem (India), Brooks Lab., Coral Labs., and Oxygenta Pharma, while Good management risk is found at Sanjiv.Parant. Average growth is noted at Nectar Lifesci., while Good growth is seen at Syschem (India) and Sanjiv.Parant, with the rest showing Below Average growth. Capital Structure is Excellent at Coral Labs., Good at Syschem (India) and Sanjiv.Parant, and Below Average at the remaining peers.Return Snapshot: Aarey Drugs has the highest 1-year return at 45.51%, while Kerala Ayurveda has the lowest at -64.41%, with Speciality Medi. not having a reported 1-year return. Additionally, Oxygenta Pharma, Brooks Lab., Nectar Lifesci., and Kerala Ayurveda all have negative six-month returns.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

8.0 k (-13.04%) Volume

Shareholding (Mar 2026)

FII

0.24%

Held by 2 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

43.43%

Why is Speciality Medicines Ltd falling/rising?

28-Jun-2026

As of 27-Jun, the stock price of Speciality Medicines Ltd is declining, currently at 200.70, reflecting a 2.1% decrease and significant underperformance compared to its sector. The stock has dropped 8.48% over the past month and is trading below all key moving averages, indicating a bearish trend.

View full answer

Which are the latest news on Speciality Medi.?

28-Jun-2026

When is the next results date for Speciality Medicines Ltd?

What does Speciality Medi. do?

11-Jun-2026

Speciality Medicines Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 180 Cr. It has no reported sales or profits for the latest quarter, a P/E ratio of 14.00, and a return on equity of 18.30%.

View full answer

How big is Speciality Medi.?

11-Jun-2026

As of 10th June, Speciality Medicines Ltd has a market capitalization of 180.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

View full answer

Who are the peers of the Speciality Medi.?

11-Jun-2026

Peers of Speciality Medi. include Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., Syschem (India), Brooks Lab., Oxygenta Pharma, Coral Labs., and Sanjiv. Parant. Aarey Drugs has the highest 1-year return at 45.51%, while Kerala Ayurveda has the lowest at -64.41%, and management risks vary from below average to good among peers.

View full answer

When is the next results date for Speciality Medicines Ltd?

22-May-2026

The next results date for Speciality Medicines Ltd is 28 May 2026.

View full answer

Compare Speciality Medi. with Similar Stocks

Sanjiv.Parant.Guj. Inject(Ker)Accretion Nutrav

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 171 Cr (Micro Cap)

P/E

14.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.25

Return on Equity

18.30%

Price to Book

2.53

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

Company does not have enough history

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

When is the next results date for Speciality Medicines Ltd?

The next results date for Speciality Medicines Ltd is scheduled for 28 May 2026....

Read full news article

Announcements

Results - Financial Results For The Half Year And Year Ended March 31 2026

28-May-2026 | Source : BSE

We hereby submit Financial Results for the Half Year and Year ended March 31 2026.

Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E On May 28 2026

28-May-2026 | Source : BSE

We hereby submit the Outcome of Board Meeting held On May 28 2026.

Board Meeting Intimation for Meeting Of Board Of Directors Of Speciality Medicines Limited To Be Held On May 28 2026

21-May-2026 | Source : BSE

Speciality Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve 1. Audited Standalone Financial Statements of the company for the financial year ended on March 31 2026. 2. To consider approve and take on record Audited Standalone Financial Results of the company for the half year and the financial Year ended on March 31 2026 as per Regulation 33 of Listing Regulations. 3. Any other matter with the permission of the Chairman.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

8.05

Debt to EBITDA (avg)

0.52

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.30

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.24%

ROCE (avg)

25.44%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.48

EV to EBIT

11.75

EV to EBITDA

11.60

EV to Capital Employed

2.98

EV to Sales

2.11

PEG Ratio

Dividend Yield

ROCE (Latest)

25.35%

ROE (Latest)

18.30%

Technicals key factors

Indicator

Weekly

Monthly

MACD

RSI

Bollinger Bands

KST

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 2 FIIs (0.24%)

Promoter with highest holding

Parthkumar Babulal Goyani (21.12%)

Highest Public shareholder

Aparna Samir Thakker (7.33%)

Individual Investors Holdings

48.57%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Speciality Medi."
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44.78",
          "val2": "30.80",
          "chgp": "45.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8.34",
          "val2": "4.41",
          "chgp": "89.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.87",
          "val2": "0.22",
          "chgp": "295.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "8.18",
          "val2": "2.68",
          "chgp": "205.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.62%",
          "val2": "14.32%",
          "chgp": "4.30%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Speciality Medi."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 29.21% vs 111.74% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 80.97% vs 145.73% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "75.29",
          "val2": "58.27",
          "chgp": "29.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "13.68",
          "val2": "9.09",
          "chgp": "50.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.32",
          "val2": "0.47",
          "chgp": "180.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "13.03",
          "val2": "7.20",
          "chgp": "80.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.17%",
          "val2": "15.60%",
          "chgp": "2.57%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Half Yearly Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

44.78

30.80

45.39%

Operating Profit (PBDIT) excl Other Income

8.34

4.41

89.12%

Interest

0.87

0.22

295.45%

Exceptional Items

0.00

Standalone Net Profit

8.18

2.68

205.22%

Operating Profit Margin (Excl OI)

18.62%

14.32%

4.30%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

75.29

58.27

29.21%

Operating Profit (PBDIT) excl Other Income

13.68

9.09

50.50%

Interest

1.32

0.47

180.85%

Exceptional Items

0.00

Standalone Net Profit

13.03

7.20

80.97%

Operating Profit Margin (Excl OI)

18.17%

15.60%

2.57%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 29.21% vs 111.74% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 80.97% vs 145.73% in Mar 2025

All Annual Results

Company CV

About Speciality Medicines Ltd

Speciality Medicines Ltd

Micro Cap

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available